Month: April 2022

FIRST QUARTER HIGHLIGHTED BY STRONG ORGANIC LOAN GROWTH, RECORD LEVELS OF NON-INTEREST INCOME & COMPLETED ACQUISITION OF COMMONWEALTH BANCSHARES LOUISVILLE, Ky., April 27, 2022 (GLOBE NEWSWIRE) — Stock Yards Bancorp, Inc. (NASDAQ: SYBT), parent company of Stock Yards Bank & Trust Company, with offices in Louisville, Central and Eastern Kentucky, as well as the Indianapolis, Indiana and Cincinnati, Ohio metropolitan markets, today reported earnings for the first quarter ended March 31, 2022. Net income for the first quarter of 2022 was $7.9 million, or $0.29 per diluted share, reflecting $19.5 million in merger expenses and $4.4 million in merger related credit loss expense for the quarter. This compares to net income of $22.7 million, or $0.99 per diluted share, for the first quarter of 2021. The results for the first...

Highlights of landmark Phase 3 ATTACK trial for sulbactam-durlobactam (SUL-DUR) presented at ECCMID 2022 annual conference SUL-DUR NDA submission on track for mid-2022 Zoliflodacin Phase 3 trial progressing; enrollment completion now anticipated in 2023WALTHAM, Mass., April 27, 2022 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), an advanced late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced its first quarter 2022 financial results and provided a business update. “During our first quarter we continued to advance our pipeline and lay the foundations of our development into a fully-integrated entity with research, development and commercialization capabilities. Our focus remains on the preparation of our NDA for sulbactam-durlobactam...

—Record revenue of $206.4 million for the quarter, and year-over-year growth of 45% as reported and 48% at constant currency —Organic revenue growth of 44% for the quarter and base business growth of 37% —Growth driven by combination of base business strength, COVID-related demand, and acquisition revenue WALTHAM, Mass., April 27, 2022 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter ended March 31, 2022. Provided in this press release are financial highlights for the quarter, updates to our financial guidance for the year 2022 and access information for today’s webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “We delivered on another outstanding quarter for the...